Does tesamorelin reduce the fat that hides abdominal muscle, and what did the FDA say about peptide calculators?

The short answer

The most-shared peptide result of the week was a user reporting visible abdominal definition after eight weeks of tesamorelin, without training or changing their diet. Tesamorelin does not do that, and the reason is anatomical rather than a matter of degree. It reduces visceral fat, which sits inside the peritoneal cavity behind the abdominal muscles. Visible definition is governed by subcutaneous fat, which sits on top of them. Tesamorelin's own FDA label reports no effect on subcutaneous adipose tissue.

In the same week, the FDA published a warning letter naming a "Tesamorelin and Ipamorelin" blend — which also closes an item we left open in our previous signal report, where we declined to name a company whose letter we could not find.

Evidence tier: Tier 1 for the FDA label, warning letter and trial data, all read directly. Tier 3 for community reports. Educational content, not medical advice.

The key points:

• Tesamorelin reduces visceral fat, not the subcutaneous layer that hides abdominal muscle.
• Trial endpoint was 26 weeks; weight change versus placebo was not statistically significant.
• 47% of trial patients exceeded 2 SDS of IGF-1 and the diabetes hazard ratio was 3.3.
• The FDA warning letter kills the RUO defence using a peptide calculator as evidence.
• CJC-1295's development was halted after a trial death — but the sponsor was ConjuChem, not Ipsen.

Why tesamorelin cannot give you abs

Evidence tier: 1 — FDA label and pivotal trial data.

Tesamorelin is a growth-hormone-releasing factor analogue approved for the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. The label carries an explicit limitation of use: "Not indicated for weight loss management."

The two pivotal 26-week randomised placebo-controlled trials, in 412 and 404 patients:

And the sentence that settles the question, verbatim from the original label: "On average, there were no adverse effects of EGRIFTA™ on lipids or subcutaneous adipose tissue (SAT)."

Tesamorelin did not reduce subcutaneous fat. That is the layer sitting between your skin and your rectus abdominis, and it is the only thing that determines whether muscle is visible. Reducing visceral fat can flatten a belly that is being pushed outward from within. It cannot reveal definition, because it does not touch the tissue doing the hiding.

This is a category error, not an exaggeration, and it is the most common one in peptide marketing copy. Three further problems compound it:

• Timeframe. The primary endpoint was week 26. The label notes effects "as early as 13 weeks." Eight weeks is under a third of the pivotal trial duration.
• Population. Every participant had HIV-associated lipodystrophy with pathologically expanded visceral fat — mean VAT 176–189 cm², mean waist 104–105 cm, mean BMI 29. Lean people were never studied.
• Magnitude. One to two centimetres of waist circumference at six months, with no significant weight change, is not a visible-abs effect.

And it reverses on stopping. In the 26-to-52-week extension, patients switched to placebo regained +25 cm² (+22%) and +24 cm² (+16%) of visceral fat. Whatever benefit exists is entirely maintenance-dependent.

The dose question is more subtle than it looks

Evidence tier: 1 — three FDA labels compared.

The reported protocol was 2 mg daily. The obvious response — that this is above the approved dose — is wrong for one product and right for the others, and the distinction matters.

The lower numbers are not dose reductions. The WR label states its basis is "comparable bioavailability between the 1.28 mg EGRIFTA WR dose and the 2 mg EGRIFTA dose" — the formulations differ, the exposure is matched.

So the accurate statement is narrow: 2 mg/day of grey-market tesamorelin powder delivers roughly 40–55% more drug than any currently marketed product delivers. Saying "the approved dose is 2 mg" is false for every product on the US market today.

What the label says about the risks

Evidence tier: 1 — label read directly.

Two findings deserve more attention than they get.

IGF-1 rises substantially. At 26 weeks, 47% of patients exceeded 2 standard deviations above normal and 36% exceeded 3 SDS. The label instructs prescribers to monitor IGF-1 and to "consider discontinuing… in patients with persistent elevations of IGF-1 levels (e.g., >3 SDS)", noting that the effects of prolonged elevation are unknown.

Glucose tolerance worsens measurably. The label reports an increased risk of developing diabetes relative to placebo, with a hazard odds ratio of 3.3 (CI 1.4, 9.6), and HbA1c ≥6.5% reached in 5% of treated versus 1% of placebo patients at week 26. The trials excluded people with type 1 or type 2 diabetes — so that signal emerged in a population pre-screened to be diabetes-free.

Tesamorelin is also contraindicated in pregnancy, active malignancy and disruption of the hypothalamic-pituitary axis, with warnings for increased neoplasm risk and fluid retention including oedema, arthralgia and carpal tunnel.

The FDA closed a loop we left open

Evidence tier: 1 — warning letter read directly.

In our last signal report we wrote that we could not locate a warning letter for one of five companies named in circulating posts, and would not publish a name against an enforcement action we could not find.

We have now found it. FDA warning letter to Royal Peptides LLC, MARCS-CMS 734884, dated 24 August 2026 and posted 1 September. It names tirzepatide, semaglutide, retatrutide, SS-31, PT-141, tesamorelin and "bimorelin" as unapproved new drugs under §505(a) — and cites the seller's page for a "Tesamorelin (10mg) and Ipamorelin (3mg)" blend, the exact combination at the centre of this week's discussion.

The footnote dismantling the research-use defence is worth quoting, because it goes further than the letters we read last time:

"Despite statements on your product labeling marketing your products 'for research use only' and 'not for human or animal consumption,' evidence obtained from your website establishes that your products are intended to be drugs for human use. In addition to the cited drug claims, you market bacteriostatic water alongside a 'peptide guide' and 'peptide calculator,' resources that collectively provide the means to prepare an injectable drug for human administration."

A dosing calculator is now cited as evidence of intent for human use. Not the marketing claims — the tool. Any vendor reasoning that a disclaimer plus careful language protects them should read that sentence twice.

Correcting the CJC-1295 story

Evidence tier: 1 — FDA evaluation memorandum and contemporaneous reporting.

A physician's post about an emergency-department presentation after peptide injection prompted a round of discussion about CJC-1295 and ipamorelin, and two widely-repeated claims need fixing.

The development halt is real, and worse than the version in circulation. From FDA's own evaluation memorandum: "ConjuChem Biotechnology withdrew CJC-1295 DAC from clinical trials in 2006 after the death of a subject involved in a phase 2 trial." Contemporaneous reporting confirms a 192-participant phase 2 in HIV-related visceral obesity, stopped on 17 July 2006.

Two corrections. The sponsor was ConjuChem, not Ipsen — we have seen Ipsen named repeatedly and it is wrong. And the cause of death was never publicly established; the "pericardial effusion" explanation that circulates is unsupported. The verified fact — a participant death of undetermined cause, after which the programme was withdrawn — is more serious than the garbled version, so precision costs nothing here.

The regulatory status is also commonly stated wrongly. CJC-1295 and ipamorelin were placed in FDA's Category 2 in September 2023 over significant safety concerns, then removed in September 2024 only because the nominators withdrew their nominations — not because the agency changed its safety view. FDA subsequently recommended to its own advisory committee that neither be added to the 503A Bulks List. Neither has ever been Category 1. Saying they are "currently Category 2" has been false since September 2024.

FDA's evaluation also notes that only three studies ever gave CJC-1295 to humans, all in healthy subjects, and that no study administered any form of it to people with a disease or condition.

On IGF-1 monitoring, which the physician recommended: the Endocrine Society guideline supports IGF-1-informed titration with high-quality evidence, but the monitoring schedule carries only a weak recommendation on low-quality evidence — and that guideline concerns recombinant growth hormone in diagnosed deficiency, not secretagogues in healthy adults. The stronger citation for this specific class is tesamorelin's own label, which mandates monitoring with a concrete action threshold.

No published case report of an emergency presentation after CJC-1295 or ipamorelin use was identified. One trap worth flagging: searches surface fatal arrhythmia and QT-prolongation reports for anamorelin, a different drug. If you see an "ipamorelin case report" cited anywhere, check it is not actually an anamorelin paper.

Two claims from the wider week

Evidence tier: 1 — company filings and primary literature.

The Samsung peptide deal is real, and the framing around it is not. Samsung Biologics announced an all-cash offer for PolyPeptide Group AG on 20 July 2026 — CHF 44.31 per share, implying roughly CHF 1.46 billion, a 40% premium. The offer prospectus published 31 August; the offer period runs 15 September to 12 October.

Two things circulating about it are wrong. The widely-quoted "$1.8 billion" is a currency conversion, not the announced figure. And PolyPeptide has been listed alongside Bachem and CordenPharma as a peer "also expanding capacity" — PolyPeptide is the acquisition target, not a third party. The underlying point holds: GLP-1 demand is industrialising peptide manufacturing, with Bachem and CordenPharma both committing large sums to new capacity.

And a longevity claim that needs its missing half. David Sinclair posted that longevity medicines might have been available around 2015 "if it weren't for a flawed study by a large pharma company that derailed a field & halted trials."

The events are real but involve two different companies. Pfizer published the 2010 paper arguing that resveratrol and related compounds do not directly activate SIRT1. Separately, GSK halted SRT501 in a myeloma trial after five patients developed acute renal failure — and GSK's stated conclusion was that the renal failure was "most likely due to the underlying disease, as kidney complications related to myeloma occur in up to 50% of cases", with the formulation offering "minimal efficacy."

Critically, GSK did not exit the field. The same statement says it was "focusing our efforts now on more selective SIRT1 activator compounds," naming two then in clinical trials. That undercuts "derailed a field" considerably.

There is also a disclosure that belongs alongside the claim: Sinclair co-founded Sirtris Pharmaceuticals, which GSK acquired in 2008 for approximately $720 million, and SRT501 was a Sirtris asset. He is criticising the company that bought and then shelved his own. We could not locate the 2026 kidney-disease finding he referenced, so we are not describing it.

Limitations

This is educational content, not medical advice.

• Community signal is self-selected and nothing here estimates how common anything is.
• 130 Reddit posts and 116 X posts over seven days from a fixed source set is not representative.
• We paraphrase community posts rather than quoting them, and do not identify users.
• The tesamorelin anecdote is unverified and we are addressing the mechanism, not the person. Unreported diet or training changes, fluid shifts, photography and co-administered compounds are all likelier explanations.
• Only the Royal Peptides letter was opened of the September sweep; we are not naming the others as verified.
• Manufacturing investment figures for Bachem, CordenPharma and Lilly were not individually opened and are directional.
• Marko Maal, MSc Pharmacy reviewed this article. Reviewer attribution does not constitute a doctor-patient relationship.

The bottom line

The tesamorelin claim is worth understanding properly because the error is structural rather than a matter of overselling. Visceral and subcutaneous fat are different tissues in different anatomical compartments, and a drug that demonstrably reduces one has a label stating it did nothing to the other. No dose or duration changes that. Anyone who developed visible definition in eight weeks did so for a reason the drug cannot explain.

The regulatory development is the more consequential one. The FDA is now citing a peptide dosing calculator as evidence that a product is intended for human use. Vendors have spent two years refining disclaimers, and the agency has moved to reading the whole site — the calculator, the bacteriostatic water, the guide — as a package that demonstrates intent regardless of what the label says.

And the CJC-1295 history deserves accuracy in both directions. The sponsor was ConjuChem. The cause of death was never established. Neither compound is currently Category 2, and the reason for removal was a withdrawn nomination rather than a safety reassessment. Each of those corrections makes the picture slightly worse for the compound, not better — which is usually how it goes when you check.

Related on this site

• Tesamorelin, Egrifta and off-label use
• CJC-1295 and ipamorelin: side effects
• GH peptides for muscle: the honest evidence
• The mouse study everyone got wrong, and the FDA letters
• GH peptides, fluid retention and carpal tunnel
• Muscle loss on GLP-1s and how to prevent it
• Peptides in Germany, Austria and Switzerland

References

• EGRIFTA WR prescribing information — indication, limitation of use, §5.2 IGF-1 monitoring, §5.4 glucose intolerance and the 3.3 hazard odds ratio, pivotal trial data. DailyMed
• EGRIFTA SV prescribing information. DailyMed
• EGRIFTA original label, 2010 — 2 mg daily dose; "no adverse effects… on lipids or subcutaneous adipose tissue (SAT)". FDA label PDF
• FDA warning letter to Royal Peptides LLC, MARCS-CMS 734884, dated 24 August 2026, posted 1 September 2026 — tesamorelin and ipamorelin blend; peptide calculator cited as evidence of intended human use. Letter
• FDA evaluation memorandum, Pharmacy Compounding Advisory Committee, 4 December 2024 — ConjuChem withdrawal of CJC-1295 DAC in 2006 following a phase 2 subject death; only three human studies, all in healthy subjects. Memorandum
• FDA, Bulk Drug Substances Nominated for Use in Compounding Under Section 503A, updated 14 May 2026 — current Category 2 list. Document
• ConjuChem phase 2 halt, July 2006 — 192 participants, HIV-related visceral obesity, stopped 17 July 2006. Contemporaneous reporting
• Samsung Biologics offer for PolyPeptide Group AG, 20 July 2026 — CHF 44.31 per share, ~CHF 1.46 billion, 40% premium. Company announcement
• GSK termination of SRT501, 30 November 2010 — renal failure attributed primarily to underlying myeloma; development continued with more selective SIRT1 activators. Reporting carrying GSK's statement
• GSK acquisition of Sirtris Pharmaceuticals, 22 April 2008 — approximately USD 720 million at USD 22.50 per share. Announcement
• Molitch ME, et al. Evaluation and Treatment of Adult Growth Hormone Deficiency: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2011;96(6):1587–1609 — recommendations 5.1 and 5.3 on IGF-1-guided titration and monitoring. Guideline